Scott Michael Palmer, MD

Professor of Medicine
Member in the Duke Clinical Research Institute
Vice-Chair for Research in the Department of Medicine
Professor in Immunology
Professor in Population Health Sciences
Core Faculty in Innovation & Entrepreneurship
Campus mail 2085 Msrb2 2 Genome Ct, Durham, NC 27710
Phone (919) 684-0245
Email address scott.palmer@duke.edu

Dr. Palmer leads a successful program of clinical, basic and translational research in transplantation and advanced lung diseases. He currently directs the pulmonary research program at the Duke Clinical Research Institute (DCRI) and serves as Vice Chair for Research in the Department of Medicine.

Dr. Palmer has over 150 peer reviewed publications, received numerous awards, including election into the American Society for Clinical Investigation (ASCI) in 2012, chaired many sessions at national and international meetings, serves regularly on NIH study sections, and is on the editorial board of many prominent journals. He is also Associate Director of the Clinical Research Training Program at Duke and has personally mentored over 40 pre-and post-doctoral trainees, many of whom are now engaged in their own successful research careers.

His scientific accomplishments include the first human studies to demonstrate the importance of innate immunity in transplant rejection and completion of a prospective multicenter study that improved CMV prevention after lung transplantation.

Current basic projects in the lab are studying the role of the matrix in the activation of innate immunity in pulmonary transplant rejection, and epithelial injury and repair in the development of toxin induced bronchiolitis obliterans. Translational and human projects are studying predictors of lung transplant survival in the UNOS database, immune monitoring to predict CMV infection and acute rejection after lung transplantation, and the use of novel inhaled antibiotics in lung transplantation. The lab is also using cutting edge whole exome genetic sequencing to identify genetic predictors of transplant rejection.

Dr. Palmer also leads trials coordinated through the DCRI that study the natural history and investigate new treatments for idiopathic pulmonary fibrosis (IPF), chronic lung transplant rejection, and posttransplant cytomegalovirus infection.

Education and Training

  • Fellow, Pulmonary Medicine, Medicine, Duke University, 1996 - 1999
  • Medical Resident, Medicine, Duke University, 1993 - 1996
  • M.H.S., Duke University, 2000
  • M.D., Duke University, 1993

Publications

Martinu, T., W. C. McManigle, F. L. Kelly, M. E. Nelson, J. Sun, H. Zhang, K. M. Gowdy, and S. M. Palmer. “IL-17 Mediates Post-Transplant Airway and Parenchymal Lung Fibrosis.” In The Journal of Heart and Lung Transplantation, 34:S175–76. Elsevier BV, 2015. https://doi.org/10.1016/j.healun.2015.01.478.

Full Text

Porteous, M., D. J. Lederer, S. M. Palmer, E. Cantu, R. J. Shah, S. Bellamny, V. N. Lama, et al. “Clinical Prediction Model for PGD Among Patients With Pulmonary Hypertension.” In The Journal of Heart and Lung Transplantation, 34:S254–55. Elsevier BV, 2015. https://doi.org/10.1016/j.healun.2015.01.706.

Full Text

Durheim, Michael T., Patrick J. Smith, Michael A. Babyak, Stephanie K. Mabe, Tereza Martinu, Karen E. Welty-Wolf, Charles F. Emery, Scott M. Palmer, and James A. Blumenthal. “Six-minute-walk distance and accelerometry predict outcomes in chronic obstructive pulmonary disease independent of Global Initiative for Chronic Obstructive Lung Disease 2011 Group..” Ann Am Thorac Soc 12, no. 3 (March 2015): 349–56. https://doi.org/10.1513/AnnalsATS.201408-365OC.

PMID
25568929
Full Text

Sayah, David M., Beñat Mallavia, Fengchun Liu, Guadalupe Ortiz-Muñoz, Axelle Caudrillier, Ariss DerHovanessian, David J. Ross, et al. “Neutrophil extracellular traps are pathogenic in primary graft dysfunction after lung transplantation..” Am J Respir Crit Care Med 191, no. 4 (February 15, 2015): 455–63. https://doi.org/10.1164/rccm.201406-1086OC.

PMID
25485813
Full Text

Smith, P. J., S. K. Rivelli, A. M. Waters, A. Hoyle, M. T. Durheim, J. M. Reynolds, M. Flowers, et al. “Delirium affects length of hospital stay after lung transplantation..” J Crit Care 30, no. 1 (February 2015): 126–29. https://doi.org/10.1016/j.jcrc.2014.09.010.

PMID
25307975
Full Text

Durheim, M. T., D. D. Cyr, S. M. Al-Khatib, L. E. Thomas, R. D. Lopes, B. J. Gersh, S. M. Palmer, and C. B. Granger. “Chronic Obstructive Pulmonary Disease Is Associated With Increased Risk Of Mortality Among Patients With Atrial Fibrillation: Insights From The Aristotle Trial.” In American Journal of Respiratory and Critical Care Medicine, Vol. 191. AMER THORACIC SOC, 2015.

Scholars@Duke

Durheim, M. T., H. R. Collard, R. S. Roberts, K. K. Brown, K. R. Flaherty, T. E. King, S. M. Palmer, et al. “Associations Between Hospitalization And Forced Vital Capacity Endpoints And Survival In Idiopathic Pulmonary Fibrosis.” In American Journal of Respiratory and Critical Care Medicine, Vol. 191. AMER THORACIC SOC, 2015.

Scholars@Duke

Todd, J. L., F. L. Kelly, D. M. Brass, V. E. Kennedy, E. N. Pavlisko, and S. M. Palmer. “Increased Amphiregulin Expression Is Associated With Chronic Allograft Dysfunction After Lung Transplantation.” In American Journal of Respiratory and Critical Care Medicine, Vol. 191. AMER THORACIC SOC, 2015.

Scholars@Duke

Chery, G. S., S. M. Palmer, L. D. Snyder, A. L. Gray, J. L. Todd, G. Harrison, and E. N. Pavlisko. “Post-Transplant Lymphoproliferative Disorder Erosion Into A Large Pulmonary Artery With Death Secondary To Hemorrhagic Shock.” In American Journal of Respiratory and Critical Care Medicine, Vol. 191. AMER THORACIC SOC, 2015.

Scholars@Duke

Chery, G. S., S. M. Palmer, L. D. Snyder, J. L. Todd, and C. Wolfe. “Brincidofovir In Progressive Multifocal Leukoencephalopathy After Lung Transplant.” In American Journal of Respiratory and Critical Care Medicine, Vol. 191. AMER THORACIC SOC, 2015.

Scholars@Duke

Pages